Alectinib rescue therapy in advanced ALK rearranged lung adenocarcinoma: a case report

Submitted: July 27, 2022
Accepted: September 14, 2022
Published: September 20, 2022
Abstract Views: 1062
PDF: 195
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


Alectinib is a highly selective tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) that is approved as first-line treatment in adult patients with ALK-positive non-small cell lung cancer (NSCLC) and as second-line in patients previously treated with crizotinib, and has been shown in the literature to significantly prolong progression-free survival compared to chemotherapy in patients with advanced non-small cell lung cancer. The authors describe a clinical case of a 24-year-old woman with malignant massive pleural effusion caused by ALK rearranged pulmonary adenocarcinoma with pleural and pericardial metastasis, in which, despite a dramatic clinical debut, the correct and timely management of the diagnostic and therapeutic path allowed for extraordinary therapeutic success.



PlumX Metrics


Download data is not yet available.


Porcel JM, Gasol A, Bielsa S, et al. Clinical features and survival of lung cancer patients with pleural effusions. Respirology 2015;20:654-9. DOI:
Comella P, Frasci G, De Cataldis G, et al. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano. Br J Cancer 1996;74:1805-11. DOI:
Cattaneo F, Guerra G, Parisi M, et al. Expression of formyl-peptide receptors in human lung carcinoma. Anticancer Res 2015;35:2769-74.
Bianco A, Perrotta F, Barra G, et al. Prognostic factors and biomarkers of responses to immune checkpoint inhibitors in lung cancer. Int J Mol Sci 2019;20:4931. DOI:
Perrotta F, Rocco D, Vitiello F, et al. Immune checkpoint blockade for advanced NSCLC: A new landscape for elderly patients. Int J Mol Sci 2019;20:2258. DOI:
Cameron LB, Hitchen N, Chandran E, et al. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. Cochrane Database Syst Rev 2022;1:CD013453. DOI:
Golding B, Luu A, Jones R, Viloria-Petit AM. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol Cancer 2018;17:52. DOI:
Moore DA, Benafif S, Poskitt B, et al. Optimising fusion detection through sequential DNA and RNA molecular profiling of non-small cell lung cancer. Lung Cancer 2021;161:55-9. DOI:
Doxtader EE, Cheng YW, Zhang Y. Molecular testing of non-small cell lung carcinoma diagnosed by endobronchial ultrasound-guided transbronchial fine-needle aspiration: The Cleveland clinic experience. Arch Pathol Lab Med 2019;143:670-6. DOI:
Perrotta F, Nankivell M, Adizie JB, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for PD-L1 testing in non-small cell lung cancer. Chest 2020;158:1230-9. DOI:
Ando K, Akimoto K, Sato H, et al. Brigatinib and alectinib for ALK rearrangement-positive advanced non-small cell lung cancer with or without central nervous system metastasis: A systematic review and network meta-analysis. Cancers (Basel) 2020;12:942. DOI:
Serritella AV, Bestvina CM. Anaplastic lymphoma kinase mutation-positive non-small cell lung cancer. Thorac Surg Clin 2020;30:137-46. DOI:

How to Cite

Cesaro, Cristiano, Umberto Caterino, Fabio Perrotta, Umberto Masi, Alessandra Cotroneo, Roberta Cianci, Enzo Zamparelli, Flavio Cesaro, Dario Amore, and Danilo Rocco. 2022. “Alectinib Rescue Therapy in Advanced ALK Rearranged Lung Adenocarcinoma: A Case Report”. Monaldi Archives for Chest Disease 93 (3).